Literature DB >> 10499523

Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor.

H Iwasaki1, S Eguchi, H Ueno, F Marumo, Y Hirata.   

Abstract

Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor peptide, exerts a growth-promoting effect on vascular smooth muscle cells, implicating its pathogenic role in vascular remodeling. To gain insight into the cellular and molecular mechanism whereby ET-1 induces vascular growth, we studied whether transactivation of receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor, are required for activation of p42/p44 mitogen-activated protein (MAP) kinase and p70 S6 kinase (p70S6K), and subsequent growth-promotion by ET-1 in cultured rat vascular smooth muscle cells. Immunoblotting with antiphosphotyrosine antibody revealed that ET-1 rapidly (within 2 min) and transiently induced tyrosine phosphorylation of several proteins, among which 180-kDa protein was shown to be EGFR. ET-1 rapidly increased association of EGFR and Shc with glutathione-S-transferase-Grb2 fusion protein. The ET-1-induced activation of MAP kinase was reduced by an EGFR kinase inhibitor (AG1478) but not by a platelet-derived growth factor receptor kinase inhibitor (AG1296). AG1478 dose-dependently decreased ET-1-stimulated MAP kinase activity as well as [3H]leucine and [3H]thymidine uptake. The ET-1-induced tyrosine phosphorylation of EGFR, as well as MAP kinase activation, was inhibited by an ETA receptor antagonist and intracellular Ca2+ antagonists but not by an ETB receptor antagonist, pertussis toxin, or protein kinase C inhibitors. In addition, dominant negative mutant of H-Ras and a MAP kinase kinase (MEK-1) inhibitor (PD98059) completely blocked ET-1-induced MAP kinase activation as well as [3H]leucine and [3H]thymidine uptake. Both AG1478 and PD98059 inhibited ET-1-induced phosphorylation and activation of p70S6K. Furthermore, rapamycin, a selective inhibitor of mammalian target of rapamycin, completely blocked ET-1-stimulated [3H]leucine and [3H]thymidine uptake. These results suggest that ETA receptor-mediated vascular growth by ET-1 requires both MAP kinase and p70S6K cascades mediated partly via Ca2+-dependent EGFR transactivation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499523     DOI: 10.1210/endo.140.10.7023

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

Review 1.  Inhibition of ENaC by endothelin-1.

Authors:  Andrey Sorokin; Alexander Staruschenko
Journal:  Vitam Horm       Date:  2015-03-06       Impact factor: 3.421

2.  Characterization and localization of Ac-SDKP receptor binding sites using 125I-labeled Hpp-Aca-SDKP in rat cardiac fibroblasts.

Authors:  Jia L Zhuo; Oscar A Carretero; Hongmei Peng; Xiao C Li; Domenico Regoli; Witold Neugebauer; Nour-Eddine Rhaleb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-10-06       Impact factor: 4.733

3.  Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer.

Authors:  Robert E Brown; George Zotalis; Ping L Zhang; Bihong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

4.  Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.

Authors:  Amal Houssaini; Shariq Abid; Nathalie Mouraret; Feng Wan; Dominique Rideau; Mirna Saker; Elisabeth Marcos; Claire-Marie Tissot; Jean-Luc Dubois-Randé; Valérie Amsellem; Serge Adnot
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

5.  EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease.

Authors:  Maria Vittoria Arcidiacono; Tetsuhiko Sato; Daniel Alvarez-Hernandez; Jing Yang; Masanori Tokumoto; Ignacio Gonzalez-Suarez; Yan Lu; Yoshihiro Tominaga; Jorge Cannata-Andia; Eduardo Slatopolsky; Adriana S Dusso
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

6.  Involvement of extracellular Ca2+ influx and epidermal growth factor receptor tyrosine kinase transactivation in endothelin-1-induced arachidonic acid release.

Authors:  Yoshifumi Kawanabe; Kazuhiko Nozaki; Nobuo Hashimoto; Tomoh Masaki
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

7.  Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System.

Authors:  Steven J Forrester; Tatsuo Kawai; Shannon O'Brien; Walter Thomas; Raymond C Harris; Satoru Eguchi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-11-09       Impact factor: 13.820

8.  Ras activation in response to lysophosphatidic acid requires a permissive input from the epidermal growth factor receptor.

Authors:  Ignacio Rubio; Knut Rennert; Ute Wittig; Reinhard Wetzker
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

Review 9.  Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification.

Authors:  N Prenzel; E Zwick; M Leserer; A Ullrich
Journal:  Breast Cancer Res       Date:  2000-03-25       Impact factor: 6.466

10.  Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway.

Authors:  Fernanda R C Giachini; Saiprasad M Zemse; Fernando S Carneiro; Victor V Lima; Zidonia N Carneiro; Glaucia E Callera; Adviye Ergul; R Clinton Webb; Rita C Tostes
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-12       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.